Table 3.

Clinical and laboratory findings dependent on TKTL1 expression status

	TKTL1/GUS ≤ Median (n = 17)	TKTL1/GUS > Median (n = 16)	P value
Median age (n = 33): 61 years	63	59	p = 0.89
Clinical tumour stage	uN negative n = 5 (29%)	uN negative n = 5 (31%)	p = 1.0
	uN positive n = 12 (71%)	uN positive n = 11 (69%)
Pathological tumour stage (n = 32)	ypT0N0 n = 1	ypT0N0 n = 2	p = 0.69
	ypT1-2N0 n = 6	ypT1-2N0 n = 6
	ypT3-4N0 n = 6	ypT3-4N0 n = 2
	ypTanyN+ n = 4	ypTanyN+ n = 5
CEA (median)	2.1	4.25	p = 0.074
CA 19-9	10	23	p = 0.18
VEGFR1 (median)	0.4125; n = 10	0.1034; n = 16	p = 0.19
VEGFR2 (median)	0.4413; n = 16	0.8241; n = 16	p = 0.11
Survivin (n = 30) (median)	6.4; n = 17	8.5; n = 13	p = 0.081
KRAS mutated (n = 14/33)	n = 6 (35%)	n = 8 (50%)	p = 0.49
Loss of PTEN (n = 2/30)	n = 1/16 (6%)	n = 1/14 (7%)	p = 1.0
Local recurrence	n = 0 (0%)	n = 2 (12.5%)	p = 0.22
Metastasis during follow up	n = 1 (6%)	n = 9 (56%)	p = 0.0024
Median DFS ∞ (months)	39	23	p = 0.017
Death	n = 2 (12%)	n = 4 (25%)	p = 0.39
Median Survival (months)	39	26	p = 0.26

∞ disease-free survival